Laurie D. Stelzer
2017
In 2017, Laurie D. Stelzer earned a total compensation of $1.8M as Senior Vice President and Chief Financial Officer at Halozyme Therapeutics, a 3% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $282,563 |
|---|---|
| Option Awards | $550,000 |
| Salary | $452,000 |
| Stock Awards | $550,006 |
| Other | $9,210 |
| Total | $1,843,779 |
Stelzer received $550K in stock awards, accounting for 30% of the total pay in 2017.
Stelzer also received $282.6K in non-equity incentive plan, $550K in option awards, $452K in salary and $9.2K in other compensation.
Rankings
In 2017, Laurie D. Stelzer's compensation ranked 5,896th out of 14,666 executives tracked by ExecPay. In other words, Stelzer earned more than 59.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,896 out of 14,666 | 60th |
Division Manufacturing | 2,148 out of 5,768 | 63rd |
Major group Chemicals And Allied Products | 670 out of 2,074 | 68th |
Industry group Drugs | 518 out of 1,730 | 70th |
Industry Biological Products, Except Diagnostic Substances | 93 out of 316 | 71st |
Source: SEC filing on March 22, 2018.
Stelzer's colleagues
We found four more compensation records of executives who worked with Laurie D. Stelzer at Halozyme Therapeutics in 2017.